RA Capital Healthcare Fund LP's Form 4 filing
LENZ Therapeutics, Inc. (LENZ) · filed Mar 25, 2024
- Accession no.
- 0001415889-24-009077
- Filed
- Mar 25, 2024, 8:48 PM ET
- Trade date
- Mar 21, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market purchases total $15.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund II, L.P.CIK 0001825376 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 21, 2024 | Common Stock | AGrant or awardAcquired | +2,386,301 | – | – | 2,386,301 | Indirect | |
| Mar 21, 2024 | Common Stock | AGrant or awardAcquired | +694,755 | – | – | 694,755 | Indirect | |
| Mar 21, 2024 | Common Stock | AGrant or awardAcquired | +164,729 | – | – | 164,729 | Indirect | |
| Mar 21, 2024 | Common Stock | PPurchaseAcquired | +933,038 | $15.03 | +$14,023,561.14 | 3,319,339 | Indirect | |
| Mar 21, 2024 | Common Stockj | PPurchaseAcquired | +64,971 | $15.03 | +$976,514.13 | 694,755 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 21, 2024 | Common Stock | AGrant or awardAcquired | +54,582 | – | – | 54,582 | Indirect | |
| Mar 21, 2024 | Common Stock | AGrant or awardAcquired | +10,580 | – | – | 10,580 | Indirect | |
| Mar 21, 2024 | Common Stock | AGrant or awardAcquired | +5,371 | – | – | 5,371 | Indirect | |
| Mar 21, 2024 | Common Stock | AGrant or awardAcquired | +27,000 | $0.00 | $0 | 27,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.